Ketamine
Ketamine is a dissociative anesthetic medication that is also used at lower doses for treatment-resistant depression and acute pain management. It works primarily through NMDA receptor antagonism, leading to rapid but often temporary changes in mood and perception. Ketamine can be administered in medical settings via IV, intranasal, or oral formulations, with effects and risks varying by dose and frequency.
-
This page summarizes anecdotal reports and community observations, not medical evidence. Reports may be incomplete, biased or inaccurate and are not medical advice or recommendations. “Risk” here refers to how frequently severe or prolonged symptom worsening is reported, not to proven causation or population-wide probability. Individual responses vary widely, and absence of issues in some users does not rule out significant reactions in others.
-
Within PFS/PSSD/PAS communities, ketamine is discussed in relation to its potential interactions with NMDA receptor signaling and neuroplasticity pathways. Ketamine's core pharmacology is NMDA-receptor antagonism, which can rapidly shift glutamate signaling and produce short-term changes in perception, mood, and pain. Mechanistically, ketamine is often discussed in terms of neuroplasticity: research reviews describe downstream effects that can increase synaptogenesis and synaptic strength, involving AMPA signaling, BDNF/TrkB, and mTOR-related pathways in various models. That said, these are general depression/neuroplasticity frameworks—not PFS/PSSD/PAS-specific mechanisms—and they don't automatically translate into durable benefit for people whose symptoms are driven by other "stuck" biology. These mechanisms may interact with pathways involving NMDA/glutamate signaling, neuroplasticity, or synaptic function that are often discussed in relation to PFS / PSSD / PAS.
-
Mixed Responses With CNS Destabilization Risks (for PFS/PSSD/PAS):
Among individuals with PFS, PSSD, or PAS, ketamine is generally described in community reports as producing mixed and often modest effects. Some users report temporary mood relief or short-lived stress buffering, while many report no meaningful change, and a subset describe worsening symptoms such as increased anxiety, sleep disruption, emotional flattening, or a destabilized “wired” feeling after treatment. Reported effects—whether helpful or harmful—are most often transient rather than durable shifts in baseline.
Ketamine is frequently viewed as acting on state rather than trait, with users describing symptomatic changes in mood or stress tolerance rather than correction of underlying mechanisms they associate with PFS, PSSD, or PAS. Although not commonly framed as a major crash trigger, ketamine is a high-impact CNS-active drug and carries recognized risks, including dissociation, sedation, respiratory depression, and misuse potential under medical labeling, as well as urinary tract injury with repeated or heavy exposure. As a result, ketamine is typically regarded as a higher-complexity, clinician-supervised option with uncertain benefit and non-trivial risk in this population.
Evidence basis Evidence basis: established pharmacology and clinical use of ketamine/esketamine; FDA safety labeling; mechanistic literature on NMDA antagonism and downstream neuroplasticity pathways; community anecdotes and self-reports.established pharmacology and clinical use of ketamine/esketamine; FDA safety labeling; mechanistic literature on NMDA antagonism and downstream neuroplasticity pathways; community anecdotes and self-reports.
-
Public comments reflect individual experiences and opinions. They are not medical advice and may not be accurate or representative.